









Markets
/
Stocks
/
nasdaq-iqv
/

IQVIA Holdings Inc

IQV

187.490USD

+6.530+3.61%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

31.80BMarket Cap

23.70P/E TTM



IQVIA Holdings Inc

187.490

+6.530+3.61%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of IQVIA Holdings Inc

Currency: USD Updated: 2026-02-06

Key Insights

IQVIA Holdings Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 4 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 250.45.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

IQVIA Holdings Inc's Score

Industry at a Glance

Industry Ranking

4 / 392

Overall Ranking

55 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

IQVIA Holdings Inc Highlights

StrengthsRisks

IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, and provides outsourced clinical research and clinical trial-related services. The Contract Sales & Medical Solutions segment provides healthcare provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. It offers a set of strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services.

Industry Leader

The company's revenue leads the industry, with the latest annual revenue totaling USD 16.31B.

Undervalued

The company’s latest PE is 23.70, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 171.05M shares, decreasing 8.41% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 3.52K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.10.

Analyst Rating

Based on 26 analysts

Buy

Current Rating

260.480

Target Price

+28.61%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of IQVIA Holdings Inc is 8.74, ranking 31 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 4.36B, representing a year-over-year increase of 10.26%, while its net profit experienced a year-over-year increase of 17.62%.

Score

Industry at a Glance

Previous score

8.74

Change



Financials

5.92

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.78

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

IQVIA Holdings Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of IQVIA Holdings Inc is 8.11, ranking 62 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is 23.70, which is 74.61% below the recent high of 41.38 and 21.95% above the recent low of 18.50.

Score

Industry at a Glance

Previous score

8.11

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 4/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of IQVIA Holdings Inc is 8.31, ranking 136 out of 392 in the Biotechnology & Medical Research industry. The average price target is 254.00, with a high of 270.00 and a low of 200.00.

Score

Industry at a Glance

Previous score

8.31

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 26 analysts

Buy

Current Rating

260.480

Target Price

+28.61%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

IQVIA Holdings Inc

IQV

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

Kymera Therapeutics Inc

KYMR

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of IQVIA Holdings Inc is 6.93, ranking 136 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 231.00 and the support level at 160.03, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.77

Change

0.16

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-13.290

Sell

RSI(14)

25.004

Sell

STOCH(KDJ)(9,3,3)

13.871

Oversold

ATR(14)

10.361

High Vlolatility

CCI(14)

-158.253

Sell

Williams %R

83.228

Oversold

TRIX(12,20)

-0.328

Sell

StochRSI(14)

25.007

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

201.198

Sell

MA10

219.199

Sell

MA20

229.329

Sell

MA50

228.116

Sell

MA100

217.328

Sell

MA200

191.912

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of IQVIA Holdings Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 100.44%, representing a quarter-over-quarter decrease of 2.80%. The largest institutional shareholder is The Vanguard, holding a total of 19.57M shares, representing 11.49% of shares outstanding, with 0.61% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

19.41M

-0.95%

Harris Associates L.P.

Star Investors

11.39M

-3.11%

BlackRock Institutional Trust Company, N.A.

9.44M

+0.72%

State Street Investment Management (US)

7.55M

-1.00%

GIC Private Limited

6.54M

-28.36%

Geode Capital Management, L.L.C.

4.35M

+3.14%

CPP Investments

4.12M

-1.27%

AllianceBernstein L.P.

3.60M

+1.17%

Boston Partners

3.56M

+80.09%

Artisan Partners Limited Partnership

3.43M

+4.92%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of IQVIA Holdings Inc is 9.18, ranking 2 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.40. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.